AZD 7009

Known as: AZD-7009, AZD7009 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2016
012320042016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BACKGROUND The atrial fibrillatory rate (AFR), on AZD7009 as compared to placebo, was investigated as a potential biomarker for… (More)
Is this relevant?
2012
2012
Pharmaceutical regulatory bodies require minimal presence of solvent in an active pharmaceutical ingredient (API) after… (More)
Is this relevant?
2009
2009
This randomized, double-blind trial compared cardioversion rates between AZD7009 infusion (15-minute 3.25 mg/min, 15-minute 4.4… (More)
Is this relevant?
2007
2007
AZD7009 (tert-Butyl-2-(7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethylcarbamate) is an… (More)
Is this relevant?
2006
2006
This study evaluated the effects of the novel antiarrhythmic agent AZD7009 on atrial and ventricular repolarization and on the Na… (More)
Is this relevant?
2006
2006
AIMS To compare the electrophysiological and antiarrhythmic effects of AZD7009, azimilide, and AVE0118 in the acutely dilated… (More)
Is this relevant?
2005
2005
AZD7009 is a novel antiarrhythmic compound in early clinical development for management of atrial fibrillation… (More)
Is this relevant?
2005
2005
BACKGROUND This study examined the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide. METHODS… (More)
Is this relevant?
2005
2005
INTRODUCTION AZD7009 is a novel anti-arrhythmic compound under development for short- and long-term management of atrial… (More)
Is this relevant?
2004
2004
INTRODUCTION We tested the hypothesis that AZD7009 terminates induced atrial fibrillation (AF) and flutter (AFL) and prevents… (More)
Is this relevant?